New CAR T approach minimizes resistance, helps avoid relapse in non-Hodgkin’s B-cell lymphoma
Early results from a new, pioneering chimeric antigen receptor (CAR) T cell immunotherapy trial found using a bilateral attack achieves a more robust defense and helps avoid relapse. Quelle: Scienc…
